Nevro (NVRO) Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings or view top-rated stocks.

14 brokerages have issued 1 year price objectives for Nevro's stock. Their NVRO share price forecasts range from $21.00 to $57.00. On average, they expect the company's share price to reach $30.62 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts.

Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 50.7% and is now trading at $19.52.
View the best growth stocks for 2023 here.

Nevro saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,390,000 shares, an increase of 27.8% from the August 15th total of 1,870,000 shares. Based on an average daily volume of 539,400 shares, the days-to-cover ratio is currently 4.4 days.
View Nevro's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our NVRO earnings forecast.

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Tuesday, August, 1st. The medical equipment provider reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The medical equipment provider earned $108.80 million during the quarter, compared to analysts' expectations of $108.19 million. Nevro had a net margin of 0.61% and a negative trailing twelve-month return on equity of 32.73%. The firm's revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.71) earnings per share.

ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Health Care Equipment ETF (XHE).Fidelity Digital Health ETF (FDHT).

Nevro issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $95.00 million-$97.00 million, compared to the consensus revenue estimate of $109.25 million.

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.37%), ArrowMark Colorado Holdings LLC (5.03%), State Street Corp (3.11%), Assenagon Asset Management S.A. (2.76%), Principal Financial Group Inc. (2.00%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends.

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $19.52.

Nevro (NYSE:NVRO) has a market capitalization of $705.06 million and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or $0.01 on an earnings per share basis.

The company employs 1,087 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.